Steatotic liver disease

There are 101 papers on steatotic liver disease in aging research: 3 trials and 79 observational studies in people, 2 in animals, 14 reviews. The newest story, Nov 21, 2026: “Fatty liver disease linked to earlier colorectal cancer risk”.

Disease

101 papers study it947 more mention it58 findings

188 new papers in 30 daysSee all 1,048 papers on steatotic liver disease

At a glance

Steatotic liver disease is linked with muscle loss, worse muscle function, and higher dementia risk in human observational studies. Several studies link it with higher mortality, while one shows no clear mortality link. A human trial reports decreased steatotic liver disease with SGLT2 inhibitors added to metformin.

58 findings in 32 papers from 2024 to 2026, 10 of them since April 2026

“those with SLD had significantly higher mortality from neoplasm (HR 1.24 (1.20, 1.28)), circulatory (1.57 (1.50, 1.64)), and digestive diseases (1.85 (1.67, 2.05))”
Unequal mortality risks in steatotic liver disease beyond liver: influence of disease subtypes and fibrosisDiabetology & metabolic syndrome2026doi:10.1186/s13098-026-02282-1
  • Human trial3
  • Humans79
  • Animals2

Interventions

4

SGLT2 inhibitors

downin humans1

1 study
  1. SGLT2 inhibitors decrease steatotic liver disease in humans (51% vs 20%).

    Human trial52-weekn = 71

  2. SGLT2 inhibitors decrease steatotic liver disease in humans (as an add-on to metformin).

    Human trialas an add-on to metformin52 consecutive weeksn = 71

More on SGLT2 inhibitors

Light physical activity

no changein humans1

1 study
  1. Light physical activity was not clearly linked with steatotic liver disease in humans.

    Humans

More on Light physical activity

Sedentary behavior

no changein humans1

1 study
  1. Sedentary behavior was not clearly linked with steatotic liver disease in humans.

    Humans

More on Sedentary behavior

Sleep

no changein humans1

1 study
  1. Sleep was not clearly linked with steatotic liver disease in humans.

    Humans

More on Sleep

Effects

5

Chronic kidney disease

no changein humans1

1 study
  1. Steatotic liver disease was not clearly linked with chronic kidney disease in humans (two-sample Mendelian randomization) (no causal effect).

    Humanstwo-sample Mendelian randomization

More on Chronic kidney disease

Muscle function

downin humans1

1 study
  1. Steatotic liver disease is linked with worse muscle function in humans (independently of age, BMI and energetic balance).

    Humansindependently of age, BMI and energetic balance

Muscle strength

downin humans1

1 study
  1. Steatotic liver disease is linked with worse muscle strength in humans (compared to age- and gender-matched controls).

    Humanscompared to age- and gender-matched controls

Mortality

no changein humans1

1 study
  1. Steatotic liver disease was not clearly linked with mortality in humans.

    Humans

Appendicular skeletal muscle mass

downin humans1

1 study
  1. Steatotic liver disease is linked with lower appendicular skeletal muscle mass in humans (-38.3 g/year (95% CI -40.3, -36.3) vs -31.0 g/year (95% CI -32.3, -29.6)).

    Humans5.9 years

More on Appendicular skeletal muscle mass

Upstream

1

Age

downin humans1

1 study
  1. Age is linked with lower steatotic liver disease in individuals with obesity (p=0.039).

    Humansin individuals with obesityn = 328

Associations

47

PanAdipo

upin humans1HR 1.33

1 study
  1. PanAdipo is associated with steatotic liver disease in humans (Exploratory health system analyses; BMI-adjusted) (HR 1.33 (1.11–1.59) per SD of log[PanAdipo]; Hartung-Knapp intervals crossed 1).

    HumansExploratory health system analyses; BMI-adjusted

    Heart ultrasound model flags fat linked to metabolic risk

    Journal of the American College of Cardiology

More on PanAdipo

Cause-specific mortality from liver-related disease, extrahepatic cancer, and cardiovascular disease

upin humans1

1 study
  1. Steatotic liver disease is associated with cause-specific mortality from liver-related disease, extrahepatic cancer, and cardiovascular disease in humans (MASLD, MetALD, and ALD compared with no steatotic liver disease).

    HumansMASLD, MetALD, and ALD compared with no steatotic liver disease

L-valine

upin humans1OR 1.78

1 study
  1. L-valine is linked with a higher risk of steatotic liver disease in humans (OR 1.78, 95% CI 1.22-2.63).

    Humansn = 754

More on L-valine

Proteus

upin humans1OR 1.32

1 study
  1. Proteus is linked with a higher risk of steatotic liver disease in humans (OR 1.32, 95% CI 1.01-1.72).

    Humansn = 754

Sedentary behavior

upin humans1HR 1.26

1 study
  1. Sedentary behavior is linked with a higher risk of steatotic liver disease in humans (HR 1.26, 95% CI 1.00-1.58).

    Humansn = 2,942

More on Sedentary behavior

Exercise

downin humans1HR 0.78

1 study
  1. Exercise is linked with a lower risk of steatotic liver disease in humans (HR 0.78, 95% CI 0.63-0.98).

    Humansn = 2,942

More on Exercise

Hepatocellular carcinoma

upin humans1

1 study
  1. Steatotic liver disease is linked with a higher risk of hepatocellular carcinoma in humans.

    Humansn = 43,994

More on Hepatocellular carcinoma

Myocardial infarction mortality

upin humans1HR 1.69

1 study
  1. Steatotic liver disease is associated with myocardial infarction mortality in humans (Compared with participants without steatotic liver disease) (HR 1.69 (1.53, 1.86)).

    HumansCompared with participants without steatotic liver diseaseMedian follow-up of 13.8 yearsn = 486,156

    Death risks linked to fatty liver varied by disease type

    Diabetology & metabolic syndrome

COVID-19 mortality

upin humans1HR 1.97

1 study
  1. Steatotic liver disease is associated with covid-19 mortality in humans (Compared with participants without steatotic liver disease) (HR 1.97 (1.76, 2.21)).

    HumansCompared with participants without steatotic liver diseaseMedian follow-up of 13.8 yearsn = 486,156

    Death risks linked to fatty liver varied by disease type

    Diabetology & metabolic syndrome

Diabetes mortality

upin humans1HR 3.4

1 study
  1. Steatotic liver disease is associated with diabetes mortality in humans (Compared with participants without steatotic liver disease) (HR 3.40 (2.59, 4.46)).

    HumansCompared with participants without steatotic liver diseaseMedian follow-up of 13.8 yearsn = 486,156

    Death risks linked to fatty liver varied by disease type

    Diabetology & metabolic syndrome
All 47

Trial sponsors

Funding

4 grants since 2023

National Institute of Diabetes and Digestive and Kidney Diseases$2.7MNational Institute for Health Research£267KWellcome Trust

Contains public sector information licensed under the Open Government Licence v3.0.

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Human studies link steatotic liver disease with muscle loss, poorer muscle function, and higher dementia risk. Mortality associations differ, including a study with no clear link. A human trial reports reduced steatotic liver disease with SGLT2 inhibitors added to metformin, while observational studies link healthier lifestyles with lower disease risk.

  2. Summary rewritten as its findings changed.

    As it read before

    One human study associates exercise with lower steatotic liver disease risk, and sedentary behavior, L-valine and Proteus with higher risk. Another links steatotic liver disease to higher hepatocellular carcinoma risk, while another links it to higher mortality.

  3. Summary written from the findings.

Latest

Dec 2025: 31Jan 2026: 91Feb 2026: 95Mar 2026: 78Apr 2026: 21May 2026: 34Jun 2026: 49Jul 2026: 50Aug 2026: 85Sep 2026: 60Oct 2026: 124Nov 2026: 88806 papers in 12 months
Research Square

Fatty liver disease linked to earlier colorectal cancer risk

People with three fatty liver disease subtypes were estimated to reach the same colorectal cancer risk 2–6 years earlier than people without fatty liver disease.People with three fatty liver disease subtypes were estimated to reach the same colorectal cancer risk 2–6 years earlier than people without fatty liver disease.

Preprint: cohort · 191,837 peopleColorectal cancer
Diabetology & Metabolic Syndrome

Death risks linked to fatty liver varied by disease type

The relative risk of death from heart and blood vessel diseases was higher with fatty liver disease than without it, with a hazard ratio of 1.57.The relative risk of death from heart and blood vessel diseases was higher with fatty liver disease than without it, with a hazard ratio of 1.57.

Cohort · 486,156 peoplePopulations
Nature Communications

A protein helps control fat breakdown in mouse livers

Experiments in mouse models of fatty liver disease showed that raising the protein’s levels protected against fat buildup and liver injury.Experiments in mouse models of fatty liver disease showed that raising the protein’s levels protected against fat buildup and liver injury.

Mouse studyMechanisms

See all 1,048 papers on steatotic liver disease